Maxalt 10 mg Norge - norsk - Statens legemiddelverk

maxalt 10 mg

n.v. organon - kloosterstraat - rizatriptanbenzoat - tablett - 10 mg

Maxalt 5 mg Norge - norsk - Statens legemiddelverk

maxalt 5 mg

n.v. organon - kloosterstraat - rizatriptanbenzoat - tablett - 5 mg

Maxalt Rapitab 10 mg Norge - norsk - Statens legemiddelverk

maxalt rapitab 10 mg

n.v. organon - kloosterstraat - rizatriptanbenzoat - smeltetablett - 10 mg

Maxalt 10 mg Norge - norsk - Statens legemiddelverk

maxalt 10 mg

2care4 - rizatriptanbenzoat - tablett - 10 mg

Octagam 100 mg/ ml Norge - norsk - Statens legemiddelverk

octagam 100 mg/ ml

octapharma (2) - immunglobulin, normalt, humant - infusjonsvæske, oppløsning - 100 mg/ ml

Sumatriptan Aurobindo 50 mg Norge - norsk - Statens legemiddelverk

sumatriptan aurobindo 50 mg

aurobindo pharma (malta) limited - floriana - sumatriptansuksinat - tablett - 50 mg

Sumatriptan Aurobindo 100 mg Norge - norsk - Statens legemiddelverk

sumatriptan aurobindo 100 mg

aurobindo pharma (malta) limited - floriana - sumatriptansuksinat - tablett - 100 mg

Octagam 50 mg/ ml Norge - norsk - Statens legemiddelverk

octagam 50 mg/ ml

octapharma (2) - immunglobulin, normalt, humant - infusjonsvæske, oppløsning - 50 mg/ ml

Flebogamma DIF (previously Flebogammadif) Den europeiske union - norsk - EMA (European Medicines Agency)

flebogamma dif (previously flebogammadif)

instituto grifols s.a. - humant normalt immunglobulin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - immune sera og immunglobuliner, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Aftovaxpur DOE Den europeiske union - norsk - EMA (European Medicines Agency)

aftovaxpur doe

boehringer ingelheim vetmedica gmbh - maksimalt tre av følgende renset, inaktivert fot-og-munn sykdom virusartene: o1 manisa ≥ 6 pd50*; o1 bfs ≥ 6 pd50*; o taiwan 3/97 ≥ 6 pd50*; a22 irak ≥ 6 pd50*; a24 cruzeiro ≥ 6 pd50*; en kalkun 14/98 ≥ 6 pd50*; asia 1 shamir ≥ 6 pd50*; sat2 saudi-arabia ≥ 6 pd50*; * pd50 – 50% beskyttende dose i storfe som er beskrevet i tlf. eur. monografi 0063. - immunologicals - pigs; cattle; sheep - aktiv immunisering av storfe, sauer og griser fra 2 ukers alder mot munn- og klovsyke for å redusere kliniske tegn.